Project Grant R44AG060843

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...

TAUTRACE: Ultrasensitive Immunoassay Platform for Alzheimer's Disease Biomarkers Adeptrix Corp received a $499,940 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective September 11, 2025, with a completion date of August 31, 2026. The company is developing TAUTRACE, an ultrasensitive immunoassay platform designed to detect and quantify phosphorylated tau (pTau) protein biomarkers in cerebrospinal fluid and plasma samples at...

This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...

This Project Grant award of $320,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is supporting research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the impact of pathological tau protein on alternative polyadenylation (APA) regulation in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in mouse primary hippocampal neurons expressing wild-type and mutant tau proteins....

This $2,190,943 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a research study conducted by the University of Alabama at Birmingham (UAB) to examine the relationship between tau protein deposition and functional brain network health in individuals at risk for Alzheimer's disease (AD). The key objectives of the study are to: 1) Use tau positron emission tomography (PET) and resting-state functional magnetic resonance imaging (fMRI) to...

This $1,823,353 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the Seattle Institute For Biomedical And Clinical Research aims to elucidate the molecular mechanisms by which pathological tau protein causes neurodegeneration in Alzheimer's disease (AD) and related tauopathy disorders. The research project will leverage a C. elegans model of tauopathy to investigate the functional role of nuclear speckles, membraneless organelles involved in RNA...

Federal Project Grant Award Summary Tauvision, Inc. received $986,768 in funding from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded September 20, 2025, with a one-year project period concluding September 19, 2026. The company will develop and optimize a novel eyedrop-based diagnostic test for detecting Alzheimer's disease (AD) biomarkers. The primary deliverable is an improved fluorescent compound formulation that can label pathological protein aggregates in the...

Summary The National Institute on Aging awarded Weill Medical College of Cornell University a $717,709 Project Grant, effective June 1, 2025 through March 31, 2030, under the Aging Research program (CFDA 93.866) to conduct research investigating proteomic changes associated with tauopathy in human neurons. The research will employ advanced proteogenomic approaches, including Ascorbic Acid Peroxidase (APEX) proximity labeling, Affinity Purification Mass Spectrometry (AP-MS), and transcriptomics...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research at Virginia Commonwealth University (VCU) to investigate the effect of the trans-synaptic spread of pathogenic tau protein in the hippocampus and its impact on vulnerable neuron subtypes in Alzheimer's disease (AD). The $408,638 award, effective from August 1, 2024 to July 31, 2026, will involve the use of adeno-associated viral vector transfection, immunofluorescence, and...